AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28625402
Drug: Drug eluting
RxNorm normalized name: Drug eluting stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug eluting stent (DES group)
Trial: 21968667
Drug: 3% oregano
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% oregano extract ointment
Trial: 16817643
Drug: Daily activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily activities (sitting, walking, running, jumping)
Trial: 12838499
Drug: Tacrolimus in
RxNorm normalized name: tacrolimus Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus in combination with MMF
Trial: 12838499
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy with MMF
Trial: 9363861
Drug: Intensive-course 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intensive-course 5-FU plus l-leucovorin with I.V. leucovorin (100 mg/m2)
Trial: 9363861
Drug: Intensive-course 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intensive-course 5-FU plus oral (d,l)-leucovorin (125 mg/m2)
Trial: 9363861
Drug: Intensive-course 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intensive-course 5-FU plus I.V. (d,l)-leucovorin (200 mg/m2)
Trial: 8239918
Drug: Vratizolin (3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vratizolin (3% hydrophilic cream or ointment, four times daily)
Trial: 8239918
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (zinc ointment, Aphtin, Oxycort, Dicortinef)
Trial: 3699121
Drug: Fenoterol powder
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol powder inhaler with fast inhalation (16-19 l/min)
Trial: 24725808
Drug: Stiripentol 500
RxNorm normalized name: stiripentol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stiripentol 500 mg
Trial: 24725808
Drug: Stiripentol 1000
RxNorm normalized name: Stiripentol
DrugBank: Stiripentol (DB09118)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Stiripentol 1000 mg
Trial: 24725808
Drug: Stiripentol 2000
RxNorm normalized name: Stiripentol
DrugBank: Stiripentol (DB09118)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Stiripentol 2000 mg
Trial: 24725808
Drug: Stiripentol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stiripentol (all doses)
Trial: 20834165
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum No. 14 (LP14) at a dosage of 8.7×10(8)
Trial: 17689732
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg b.i.d.)
Trial: 15842286
Drug: PgE(2) 1
RxNorm normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PgE(2) 1 mg
Trial: 15842286
Drug: PgE(2) 2
RxNorm normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PgE(2) 2 mg
Trial: 11831913
Drug: 2'7'‐bis‐(2‐carboxyethyl)‐5‐(and‐6)‐carboxyfluorescein, acetoxymethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2'7'‐bis‐(2‐carboxyethyl)‐5‐(and‐6)‐carboxyfluorescein, acetoxymethyl ester (80 microg) applied via subconjunctival injection 15 minutes prior to trabeculectomy, followed by intraoperative illumination with diffuse blue light (450‐490 nm) for 8 minutes
Trial: 8613282
Drug: Metronidazole 7.5
RxNorm normalized name: metronidazole 7.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 7.5 mg/kg thrice daily for 5 days
Trial: 2125241
Drug: Gallopamil infusion
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil infusion (0.03 mg/kg bolus followed by continuous infusion at 0.02 mg/kg/h for the first 24 hours and 0.03 mg/kg/h for the last 48 hours)
Trial: 2125241
Drug: Gallopamil infusion
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil infusion
Trial: 161694
Drug: Plasmin inhibitors
RxNorm normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmin inhibitors measured with a functional assay
Trial: 30284385
Drug: Topical cyclosporine-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine-A 2% eye drops
Trial: 26530718
Drug: JinQi Jiangtang
RxNorm normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JinQi Jiangtang tablets
Trial: 21070228
Drug: Topiramate plus
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate plus placebo injections
Trial: 21070228
Drug: OnabotulinumtoxinA injections
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA injections plus placebo tablets
Trial: 19577745
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution lavage
Trial: 8810653
Drug: Cadralazine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadralazine (single oral dose)
Trial: 3868306
Drug: Rectally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectally administered diazepam (0.6 mg/kg)
Trial: 31258108
Drug: Sucralose (780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralose (780 mg/d for 7 days)
Trial: 25311296
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (including selective estrogen receptor modulators, selective estrogen receptor downregulators, and aromatase inhibitors)
Trial: 8945073
Drug: Propafenone (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (450 or 600 mg)
Trial: 8945073
Drug: Digoxin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (1 mg) or Placebo
Trial: 1769127
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 2 IU/m2 subcutaneously daily for 4 months
Trial: 26613620
Drug: Daily meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily meal delivery
Trial: 26613620
Drug: Once-weekly meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly meal delivery
Trial: 12733709
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - conjugated estrogens (0.625 mg/day) and medroxyprogesterone (2.5 mg/day) for 12 months
Trial: 10227010
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 hormone replacement therapy
Trial: 8755201
Drug: 0.4 mg/ml
RxNorm normalized name: thymol 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/ml mitomycin C
Trial: 8755201
Drug: 0.2 mg/ml
RxNorm normalized name: iodine 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/ml mitomycin C
Trial: 8755201
Drug: 0.1 mg/ml
RxNorm normalized name: deanol 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/ml mitomycin C
Trial: 1848996
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (control) - standard alternating chemotherapy regimen
Trial: 1848996
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (investigative) - simultaneous administration of cyclophosphamide + lomustine alternating with cyclophosphamide + doxorubicin, and doxorubicin + lomustine
Trial: 7075640
Drug: Labetalol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (100 mg tid)
Trial: 7075640
Drug: Clonidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.1 mg tid)
Trial: 30539384
Drug: MPFF 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPFF 1000 mg/day for 6 months
Trial: 30539384
Drug: Oral rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral rivaroxaban for 6 months (Control)
Trial: 28371242
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (IN-OT) for 5 days
Trial: 28371242
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo spray for 5 days
Trial: 26015309
Drug: Cyclic 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic 15 mg MPA
Trial: 26015309
Drug: Continuous 15
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 15 mg MPA
Trial: 19657698
Drug: Exponential decrease
RxNorm normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exponential decrease group (group 1) vs. Nearly exponential decrease group (group 2) and Randomized clearance group (group 3) in stage II rectal cancer
Trial: 9657561
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) 336 microg x day(‐1)
Trial: 8593713
Drug: Terbinafine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (250 mg daily) for 6 weeks
Trial: 8593713
Drug: Terbinafine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (250 mg daily) for 12 weeks
Trial: 2675580
Drug: Oxybutynin 5
RxNorm normalized name: oxyBUTYnin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 5 mg twice daily
Trial: 1090796
Drug: Electron beam
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electron beam therapy
Trial: 1090796
Drug: Topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy and external irradiation
Trial: 28758716
Drug: 4% TiF4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% TiF4 gel applied three times (TiF4 3)
Trial: 28758716
Drug: 4% TiF4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% TiF4 gel applied twice (TiF4 2)
Trial: 28758716
Drug: 4% TiF4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% TiF4 gel applied once (TiF4 1)
Trial: 28758716
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C1) - no treatment, 2 days of erosive/abrasive cycling
Trial: 28758716
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C2) - no treatment, 4 days of erosive/abrasive cycling
Trial: 28758716
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C3) - no treatment, 6 days of erosive/abrasive cycling
Trial: 23473987
Drug: Acamprosate (anticraving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (anticraving substance) administered for 3 months
Trial: 21438799
Drug: Relapse Prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse Prevention (RP) group therapy over a 2-month period
Trial: 21438799
Drug: Labor Rehabilitation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Labor Rehabilitation (LR) standard-of-care treatment
Trial: 21438799
Drug: Relapse Prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse Prevention (RP) group therapy
Trial: 16453054
Drug: 20-week, twice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-week, twice-weekly exercise program (EX1)
Trial: 16453054
Drug: 20-week, twice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-week, twice-weekly exercise program (EX2)
Trial: 15112279
Drug: Specialized, nutrition‐focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized, nutrition‐focused patient care (oral nutritional support and home total parenteral nutrition [TPN]) along with COX inhibitor (indomethacin, 50 mg twice daily) and EPO (15‐40,000 units per week)
Trial: 11665788
Drug: Phosphodiesterase inhibitors
RxNorm normalized name: Phosphodiesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase inhibitors (PDEI)
Trial: 9743450
Drug: Hydrophilic matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrophilic matrix tablet (ER)
Trial: 9743450
Drug: Push‐pull osmotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Push‐pull osmotic pump tablet (XL)
Trial: 9743450
Drug: Hydrophilic matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrophilic matrix tablet (ER) with food
Trial: 9743450
Drug: Push‐pull osmotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Push‐pull osmotic pump tablet (XL) with food
Trial: 7974365
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of heparin (LDH)
Trial: 7974365
Drug: Heparin-dihydergot (HDHE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-dihydergot (HDHE)
Trial: 2564280
Drug: Vecuronium administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium administered to 50% of the patients in each anaesthetic group
Trial: 4936366
Drug: Intravenous prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prednisolone (1 Gm.)
Trial: 23863876
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg × 2)
Trial: 23863876
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m²)
Trial: 14506952
Drug: HRT (piperazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (piperazine estrone sulfate 0.625 - 1.25 mg/d +/− medroxyprogesterone acetate 2.5 - 5 mg/d)
Trial: 8682134
Drug: Metoprolol (Seloken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (Seloken ZOC 200 mg o.d.)
Trial: 31072190
Drug: Paracetamol and
RxNorm normalized name: Paracetamol and tramadol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol and Ibuprofen
Trial: 22270734
Drug: Cervical interlaminar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical interlaminar epidural injections of local anesthetic (lidocaine 0.5%, 5 mL) - Group I
Trial: 22270734
Drug: Cervical interlaminar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical interlaminar epidural injections with 0.5% lidocaine, 4 mL, mixed with 1 mL of nonparticulate betamethasone - Group II
Trial: 19798060
Drug: Investigational phosphodiesterase
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational phosphodiesterase type 5 inhibitor
Trial: 17621727
Drug: Ginger (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (650 mg, three times per day for 4 days)
Trial: 17621727
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 (25 mg, three times per day for 4 days)
Trial: 7661937
Drug: Oral captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral captopril (6.25 mg initial dose titrated up to 50 mg twice daily)
Trial: 7661937
Drug: Oral controlled-release
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral controlled-release mononitrate (30 mg initial dose titrated up to 60 mg once daily)
Trial: 7661937
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (8 mmol initial bolus followed by 72 mmol for 24 hours)
Trial: 3047333
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with cyclophosphamide, fluorouracil, prednisone (CFP)
Trial: 28089141
Drug: rHA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHA vaccine at 7.5ug (no adjuvant)
Trial: 28089141
Drug: rHA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHA vaccine at 3.8ug with 2% SE
Trial: 28089141
Drug: rHA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHA vaccine at 7.5ug with 2% SE
Trial: 28089141
Drug: rHA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHA vaccine at 15ug with 2% SE
Trial: 16221219
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg three times a day
Trial: 16221219
Drug: Both active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both active treatments (Celecoxib and Indomethacin)
Trial: 12148101
Drug: Sodium-profiling hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-profiling hemodialysis with dialysate sodium concentration of 140 mmol/L (TAC(140))
Trial: 12148101
Drug: Sodium-profiling hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-profiling hemodialysis with dialysate sodium concentration of 147 mmol/L (TAC(147))
Trial: 12148101
Drug: Conventional hemodialysis
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional hemodialysis with dialysate sodium concentration of 138 mmol/L (TAC(138))
Trial: 3076790
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose enprofylline (2 mg/kg bolus and 1 mg/kg/hour infusion)
Trial: 3076790
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose enprofylline (1 mg/kg bolus and 500 micrograms/kg/hour infusion)
Trial: 3076790
Drug: Aminophylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (5 mg/kg bolus and 500 micrograms/kg/hour infusion)
Trial: 21050476
Drug: Ezetimibe/Simvastatin 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/Simvastatin 10/20 mg (EZ/Simva)
Trial: 21050476
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg (Rosuva)
Trial: 17577218
Drug: Ixabepilone 35
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone 35 mg/m² intravenously every 3 weeks
Trial: 17577218
Drug: Mitoxantrone 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 14 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily
Trial: 17577218
Drug: Third-line crossover
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-line crossover treatment
Trial: 3133709
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg trazodone nocte
Trial: 3133709
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg trazodone t.d.s.
Trial: 16831143
Drug: Bicalutamide 150
RxNorm normalized name: bicalutamide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150 mg/day for 3 months
Trial: 12746164
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (daily iron administration)
Trial: 12746164
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment (iron administration 2 days a week)
Trial: 8724062
Drug: Ceftibuten (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten (9 mg/kg/day in one daily dose)
Trial: 8724062
Drug: Amoxicillin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (40 mg/kg/day divided into 3 daily doses)
Trial: 31446847
Drug: Transport directly
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transport directly to a comprehensive stroke center for intravenous thrombolysis and endovascular therapy
Trial: 31446847
Drug: Transport to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transport to a primary stroke center for intravenous thrombolysis and subsequent transport to a comprehensive stroke center for endovascular therapy if needed
Trial: 31519320
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg once daily for up to 24 months
Trial: 24954228
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m² and cisplatin 75 mg/m² on day 1 (arm A)